Current and future studies with DAAs in acute HCV. Reproduced with permission.
| Study name | Coordinator | DAAs | HCV genotype | Duration, weeks | HIV status |
|---|---|---|---|---|---|
| DAHHS | Erasmus MC | BOC + pegIFN + RBV | 1 | 12 | Pos |
| CHAT | UKB | TPV + pegIFN + RBV | 1 | 12 | Pos |
| DARE-C I | Kirby Institute | TPV + pegIFN + RBV | 1 | 8–24 | Neg + pos |
| DARE-C II | Kirby Institute | SOF + RBV | All | 6 | Neg + pos |
| SWIFT-C | ACTG | SOF + RBV | All | 8 vs 12 | Pos |
| SOL | UKB | SOF + LDV | 1,4 | 6 | Pos |
| Hep-Net Acute HCV | MHH | SOF + LDV | 1 | 6 | Neg |
BOC = boceprevir; DAAs = direct-acting antivirals; HCV = hepatitis C virus; LDV = ledipasvir; pegIFN = pegylated interferon; RBV = ribavirin; SOF = sofosbuvir; TPV = telaprevir.